1 / 5

Ang1 and Tie2 were the biomarkers of main interest in this study.

Ang1 and Tie2 were the biomarkers of main interest in this study. We initially confirmed, as these were measured on the same plex , that they were independent of each other (Figure S1). Standard arm. Bevacizumab arm. 100. 100. 75. 75. 50. 50. % of patients progression-free.

vito
Télécharger la présentation

Ang1 and Tie2 were the biomarkers of main interest in this study.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ang1 and Tie2 were the biomarkers of main interest in this study. We initially confirmed, as these were measured on the same plex, that they were independent of each other (Figure S1).

  2. Standard arm Bevacizumab arm 100 100 75 75 50 50 % of patients progression-free % of patients progression-free 25 25 Median survival (months) Low Ang1 = 16.9 High Ang1 = 17.8 Median survival (months) Low Ang1 = 19.3 High Ang1 = 15.3 0 0 0 6 12 18 24 30 0 6 12 18 24 30 Time in months Time in months Number at risk Low Ang1 High Ang1 Number at risk Low Ang1 High Ang1 19 18 14 7 6 4 27 27 23 16 6 2 25 23 17 10 5 1 20 20 15 9 5 2 Figure S3a

  3. Standard arm Bevacizumab arm 100 100 75 75 50 50 % of patients progression-free % of patients progression-free 25 25 Median survival (months) Low Tie2 = 17.0 High Tie2 = 17.4 Median survival (months) Low Tie2 = 23.0 High Tie2 = 15.3 0 0 0 6 12 18 24 30 0 6 12 18 24 30 Time in months Time in months Number at risk Low Tie2 High Tie2 Number at risk Low Tie2 High Tie2 19 18 14 6 4 3 26 26 23 17 8 3 25 23 17 11 7 2 21 21 15 8 3 1 Figure S3b

  4. Standard arm Bevacizumab arm 100 100 75 75 50 50 % of patients progression-free % of patients progression-free Median survival (months) High Ang1 / low Tie2 = 23.0 Others = 17.9 Median survival (months) High Ang1 / low Tie2 = 16.2 Others = 17.4 25 25 0 0 0 6 12 18 24 30 0 6 12 18 24 30 Time in months Time in months Number at risk High Ang1/Low Tie2 Others Number at risk High Ang1/Low Tie2 Others 9 9 6 2 0 0 11 11 9 8 5 2 35 32 25 15 11 5 36 36 29 17 6 2 Figure S3c

More Related